Journal of Cell Communication and Signaling

, Volume 12, Issue 3, pp 513–527 | Cite as

Mechanistic regulation of epithelial-to-mesenchymal transition through RAS signaling pathway and therapeutic implications in human cancer

  • Kiran Tripathi
  • Minal GargEmail author


RAS effector signaling instead of being simple, unidirectional and linear cascade, is actually recognized as highly complex and dynamic signaling network. RAF-MEK-ERK cascade, being at the center of complex signaling network, links to multiple scaffold proteins through feed forward and feedback mechanisms and dynamically regulate tumor initiation and progression. Three isoforms of Ras harbor mutations in a cell and tissue specific manner. Besides mutations, their epigenetic silencing also attributes them to exhibit oncogenic activities. Recent evidences support the functions of RAS oncoproteins in the acquisition of tumor cells with Epithelial-to-mesenchymal transition (EMT) features/ epithelial plasticity, enhanced metastatic potential and poor patient survival. Google Scholar electronic databases and PubMed were searched for original papers and reviews available till date to collect information on stimulation of EMT core inducers in a Ras driven cancer and their regulation in metastatic spread. Improved understanding of the mechanistic basis of regulatory interactions of microRNAs (miRs) and EMT by reprogramming the expression of targets in Ras activated cancer, may help in designing effective anticancer therapies. Apparent lack of adverse events associated with the delivery of miRs and tissue response make ‘drug target miRNA’ an ideal therapeutic tool to achieve progression free clinical response.


Epithelial-to-mesenchymal transition (EMT) EMT-activating transcription factors MicroRNAs RAS activation and effector proteins RAS signaling 



One of the co-authors, KT is thankful to University Grants Commission (UGC), Govt. of India for providing research fellowship.

Compliance with ethical standards


Authors disclose no potential conflict-of interests.


  1. Ahmed N, Maines-Bandiera S, Quinn MA, Unger WG, Dedhar S, Auersperg N (2006) Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. Am J Phys Cell Phys 290(6):C1532–C1542CrossRefGoogle Scholar
  2. Akagi K, Uchibori R, Yamaguchi K, Kurosawa K, Tanaka Y, Kozu T (2007) Characterization of a novel oncogenic K-RAS mutation in colon cancer. Biochem Biophys Res Commun 352:728–732PubMedCrossRefGoogle Scholar
  3. Amankwatia EB, Chakravarty P, Carey A, Weidlich S, Steele RJ, Munro AJ, Wolf CR, Smith G (2015) MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by K-RAS-dependent an independent mechanisms. Br J Cancer 112(9):1480–1490PubMedPubMedCentralCrossRefGoogle Scholar
  4. Andreolas C, Kalogeropoulou M, Voulgari A, Pintzas A (2008) Fra-1 regulates vimentin during ha-RAS-induced epithelial mesenchymal transition in human colon carcinoma cells. Int J Cancer 122:1745–1756PubMedCrossRefGoogle Scholar
  5. Atreya CE, Corcoran RB, Kopetz S (2015) Expanded RAS: refining the patient population. J Clin Oncol 33(7):682–685PubMedPubMedCentralCrossRefGoogle Scholar
  6. Baksh S, Tommasi S, Fenton S, VC Y, Martins LM, Pfeifer GP, Latif F, Downward J, Neel BG (2005) The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death. Mol Cell 18(6):637–650PubMedCrossRefGoogle Scholar
  7. Banerjee SK, Zoubine MN, Mullick M, Weston AP, Cherian R, Campbell DR (2000) Tumor angiogenesis in chronic pancreatitis and pancreatic adenocarcinoma: impact of K-ras mutations. Pancreas 20(3):248–255PubMedCrossRefGoogle Scholar
  8. Basbous J, Chalbos D, Hipskind R, Jariel-Encontre I, Piechaczyk M (2007) Ubiquitin-independent degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilize. Mol Cell Biol 27:3936–3950PubMedPubMedCentralCrossRefGoogle Scholar
  9. Batlle E, Sancho E, Francí C, Domínguez D, Monfar M, Baulida J, García D, Herreros A (2000) The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2:84–89PubMedCrossRefGoogle Scholar
  10. Bhatia S, Monkman J, Toh AKL, Nagaraj SH, Thompson EW (2017) Targeting epithelial-mesenchymal plasticity in cancer: clinical and preclinical advances in therapy and monitoring. Biochem J 474(19):3269–3306PubMedCrossRefGoogle Scholar
  11. Blaj C, Schmidt EM, Lamprecht S, Hermeking H, Jung A, Kirchner T, Horst D (2017) Oncogenic effects of high MAPK activity in colorectal cancer mark progenitor cells and persist irrespective of RAS mutations. Cancer Res 77(7):1763–1774PubMedCrossRefGoogle Scholar
  12. Bos JL, Rehmann H, Wittinghofer A (2007) GEFs and GAPs: critical elements in the control of small G proteins. Cell 129:865–877PubMedCrossRefGoogle Scholar
  13. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF, Goodall GJ (2008) A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 68:7846–7854PubMedCrossRefGoogle Scholar
  14. Brummelkamp TR, Bernards R, Agami R (2002) Stable suppression of tumorigenicity by virus mediated RNA interference. Cancer Cell 2(3):243–247PubMedCrossRefGoogle Scholar
  15. Buday L, Downward J (1993) Epidermal growth factor regulates p21Ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell 73(3):611–620PubMedCrossRefGoogle Scholar
  16. Burgess MR, Hwang E, Mroue R, Bielski CM, Wandler AM, Huang B, Firestone AJ, Young A, LaCap JA, Crocker L, Asthana S, Davis EM, Xu J, Akagi K, Le Beau MM, Li Q, Haley B, Stokoe D, Sampath D, Taylor BS, Evangelista M, Shannon K (2017) KRAS allelic imbalance enhances fitness and modulates MAP kinase dependence in cancer. Cell 168(5):817–829PubMedPubMedCentralCrossRefGoogle Scholar
  17. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T (2008) A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 9:582–589PubMedPubMedCentralCrossRefGoogle Scholar
  18. Cancer Genome Atlas Research Network. Electronic address:; Cancer Genome Atlas Research Network (2017) Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32(2):185–203.e13CrossRefGoogle Scholar
  19. Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA (2000) The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2:76–83PubMedCrossRefGoogle Scholar
  20. Capon DJ, Chen EY, Levinson AD, Seeburg PH, Goeddel DV (1983) Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue. Nature 302(5903):33–37PubMedCrossRefGoogle Scholar
  21. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC (1998) Regulation of cell death protease caspase-9 by phosphorylation. Science 282(5392):1318–1321PubMedCrossRefGoogle Scholar
  22. Casalino L, De CD, Verde P (2003) Accumulation of Fra-1 in Ras-transformed cells depends on both transcriptional autoregulation and MEK-dependent posttranslational stabilization. Mol Cell Biol 23:4401–4415PubMedPubMedCentralCrossRefGoogle Scholar
  23. Castellano E, Downward J (2011) RAS interaction with PI3K: more than just another effector pathway. Genes Cancer 2:261–274PubMedPubMedCentralCrossRefGoogle Scholar
  24. Castellano E, Sheridan C, Thin MZ, Nye E, Spencer-Dene B, Diefenbacher ME, Moore C, Kumar MS, Murillo MM, Gronroos E, Lassailly F, Stamp G, Downward J (2013) Requirement for interaction of PI3-kinase p110a with RAS in lung tumor maintenance. Cancer Cell 24:617–630PubMedPubMedCentralCrossRefGoogle Scholar
  25. Chen KJ, Hou Y, Wang K, Li J, Xia Y, Yang XY, Lv G, Xing XL, Shen F (2014) Reexpression of let-7g microRNA inhibits the proliferation and migration via K-Ras/HMGA2/snail axis in hepatocellular carcinoma. Biomed Res Int 2014:742417PubMedPubMedCentralGoogle Scholar
  26. Chen SJ, Chen YT, Zeng LJ, Zhang QB, Lian GD, Li JJ, Yang KG, Huang CM, Li YQ, Chu ZH, Huang KH (2016) Bmi1 combines with oncogenic KRAS to induce malignant transformation of human pancreatic duct cells in vitro. Tumour Biol 37(8):11299–11309PubMedCrossRefGoogle Scholar
  27. Chen Z, Wang X, Liu R, Chen L, Yi J, Qi B, Shuang Z, Liu M, Li X, Li S, Tang H (2017) KDM4B-mediated epigenetic silencing of miRNA-615-5p augments RAB24 to facilitate malignancy of hepatoma cells. Oncotarget 8(11):17712–17725PubMedGoogle Scholar
  28. Cherfils J, Zeghouf M (2013) Regulation of small GTPases by GEFs, GAPs, and GDIs. Physiol Rev 93:269–309PubMedCrossRefGoogle Scholar
  29. Chien Y, White MA (2003) RAL GTPases are linchpin modulators of human tumour-cell proliferation and survival. EMBO Rep 4(8):800–806PubMedPubMedCentralCrossRefGoogle Scholar
  30. Clark EA, Golub TR, Lander ES, Hynes RO (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406:532–535PubMedCrossRefGoogle Scholar
  31. Clarke S (1992) Protein-terminal isoprenylation and methylation at carboxyl cysteine residues. Annu Rev Biochem 61:355–386PubMedCrossRefGoogle Scholar
  32. Cox AD, Der CJ (2010) RAS history: the saga continues. Small GTPases 1(1):2–27PubMedPubMedCentralCrossRefGoogle Scholar
  33. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ (2014) Drugging the undruggable RAS: mission possible? Nat Rev 13(11):828–851Google Scholar
  34. Diaz-Meco MT, Lozano J, Municio MM, Berra E, Frutos S, Sanz L, Moscat J (1994) Evidence for the in vitro and in vivo interaction of Ras with protein kinase C zet. J Biol Chem 269(50):31706–31710PubMedGoogle Scholar
  35. Diesch J, Sanij E, Gilan O, Love C, Tran H, Fleming NI, Ellul J, Amalia M, Haviv I, Pearson RB, Tulchinsky E, Mariadason JM, Sieber OM, Hannan RD, Dhillon AS (2014) Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells. PLoS One 9(3):e88950PubMedPubMedCentralCrossRefGoogle Scholar
  36. Edkins S, O’Meara S, Parker A, Stevens C, Reis M, Jones S, Greenman C, Davies H, Dalgliesh G, Forbes S, Hunter C, Smith R, Stephens P, Goldstraw P, Nicholson A, Chan TL, Velculescu VE, Yuen ST, Leung SY, Stratton MR, Futreal PA (2006) Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 5:928–932PubMedPubMedCentralCrossRefGoogle Scholar
  37. Edme N, Downward J, Thiery JP, Boyer B (2002) Ras induces NBT-II epithelial cell scattering through the coordinate activities of Rac and MAPK pathways. J Cell Sci 115:2591–2601PubMedGoogle Scholar
  38. Eijkelenboom A, Burgering BM (2013) FOXOs: signaling integrators for homeostasis maintenance. Nat Rev Mol Cell Biol 14:83–97PubMedCrossRefGoogle Scholar
  39. Feng J, Wang X, Zhu W, Chen S, Feng C (2017) MicroRNA-630 suppresses epithelial-to-mesenchymal transition by regulating FoxM1 in gastric cancer cells. Biochemistry (Mosc) 82(6):707–714CrossRefGoogle Scholar
  40. Ferro E, Trabalzini L (2010) RalGDS family members couple Ras to Ral signalling and that’s not all. Cell Signal 22:1804–1810PubMedCrossRefGoogle Scholar
  41. Garg M (2013) Epithelial-mesenchymal transition- activating transcription factors – multifunctional regulators in cancer. World Journal of Stem Cells 5(4):188–195PubMedPubMedCentralCrossRefGoogle Scholar
  42. Garg M (2015) Targeting microRNAs in epithelial mesenchymal transition induced cancer stem cells: therapeutic approaches in cancer. Expert opinion in therapeutic. Targets 19(2):285–297Google Scholar
  43. Garg M (2017) Epithelial, mesenchymal and hybrid epithelial/ mesenchymal phenotypes and their clinical relevance in cancer metastasis. Expert Rev Mol Med 19:e3PubMedCrossRefGoogle Scholar
  44. Gebeshuber CA, Zatloukal K, Martinez J (2009) miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep 10(4):400–405PubMedPubMedCentralCrossRefGoogle Scholar
  45. Gonzalez-Garcia A, Pritchard CA, Paterson HF, Mavria G, Stamp G, Marshall CJ (2005) RALGDS is required for tumor formation in a model of skin carcinogenesis. Cancer Cell 7:219–226PubMedCrossRefGoogle Scholar
  46. Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M, Liu T, Simons JW, O'Regan RM (2008) Insulin-like growth factor-independent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 68(7):2479–2488PubMedCrossRefGoogle Scholar
  47. Grant ML, Bruton RK, Byrd PJ, Gallimore PH, Steele JC, Taylor AM, Grand RJ (1990) Sensitivity to ionising radiation of transformed human cells containing mutant Ras genes. Oncogene 5(8):1159–1164PubMedGoogle Scholar
  48. Greenburg G, Hay ED (1982) Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. J Cell Biol 95(1):333–339PubMedCrossRefGoogle Scholar
  49. Greenburg G, Hay ED (1986) Cytodifferentiation and tissue phenotype change during transformation of embryonic lens epithelium to mesenchyme-like cells in vitro. Dev Biol 115(2):363–379PubMedCrossRefGoogle Scholar
  50. Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, Nicke B, Nye E, Stamp G, Alitalo K, Downward J (2007) Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129:957–968PubMedCrossRefGoogle Scholar
  51. Heid I, Lubeseder-Martellato C, Sipos B, Mazur PK, Lesina M, Schmid RM, Siveke JT (2011) Early requirement of RAC1 in a mouse model of pancreatic cancer. Gastroenterology 141:719–730.e7PubMedCrossRefGoogle Scholar
  52. Herranz N, Pasini D, Díaz VM, Francí C, Gutierrez A, Dave N, Escrivà M, Hernandez-Muñoz I, Di Croce L, Helin K, García de Herreros A, Peiró S (2008) Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol Cell Biol 28:4772–4781PubMedPubMedCentralCrossRefGoogle Scholar
  53. Hobbs G, Der C, Rossman K (2016) RAS isoforms and mutations in cancer at a glance. J Cell Sci 129(7):1287–1292PubMedPubMedCentralCrossRefGoogle Scholar
  54. Huang H, Daniluk J, Liu Y, Chu J, Li Z, Ji B, Logsdon CD (2014) Oncogenic K-Ras requires activation for enhanced activity. Oncogene 33(4):532–535PubMedCrossRefGoogle Scholar
  55. Hüsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G, Klein CA (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13:58–68PubMedCrossRefGoogle Scholar
  56. Jiang HL, Sun HF, Gao SP, Li LD, Hu X, Wu J, Jin W (2015) Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling. Oncotarget 6(18):16352–16365PubMedPubMedCentralCrossRefGoogle Scholar
  57. Kanda M, Matthaei H, Wu J, Hong SM, Yu J, Borges M, Hruban RH, Maitra A, Kinzler K, Vogelstein B, Goggins M (2012) Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 142(4):730–733 e9PubMedPubMedCentralCrossRefGoogle Scholar
  58. Kaplan DR, Morrison DK, Wong G, McCormick F, Williams LT (1990) PDGF beta-receptor stimulates tyrosine phosphorylation of GAP and association of GAP with a signaling complex. Cell 61:125–133PubMedCrossRefGoogle Scholar
  59. Karaguni IM, Herter P, Debruyne P, Chtarbova S, Kasprzynski A, Herbrand U, Ahmadian MR, Glüsenkamp KH, Winde G, Mareel M, Möröy T, Müller O (2002) The new sulindac derivative IND 12 reverses RAS-induced cell transformation. Cancer Res 62:1718–1723PubMedGoogle Scholar
  60. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ (1992) Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci U S A 89(14):6403–6407PubMedPubMedCentralCrossRefGoogle Scholar
  61. Kent OA, Mendell JT, Rottapel R (2016) Transcriptional regulation of miR-31 by oncogenic K-RAS mediates metastatic phenotypes by repressing RASA1. Mol Cancer Res 14:267–277PubMedPubMedCentralCrossRefGoogle Scholar
  62. Kim KLZ, Hay ED (2002) Direct evidence for a role of β-catenin/LEF-1 signaling pathway in induction of EMT. Cell Biol Int 26:463–476PubMedCrossRefGoogle Scholar
  63. Kim RK, Suh Y, Yoo KC, Cui YH, Kim H, Kim MJ, Gyu Kim I, Lee SJ (2015) Activation of K-RAS promotes the mesenchymal features of basal-type breast cancer. Exp Mol Med 47:e137PubMedPubMedCentralCrossRefGoogle Scholar
  64. Kissil JL, Walmsley MJ, Hanlon L, Haigis KM, Bender Kim CF, Sweet-Cordero A, Eckman MS, Tuveson DA, Capobianco AJ, Tybulewicz VL, Jacks T (2007) Requirement for RAC1 in a KRAS induced lung cancer in the mouse. Cancer Res 67:8089–8094PubMedCrossRefGoogle Scholar
  65. Koh M, Woo Y, Valiathan RR, Jung HY, Park SY, Kim YN, Kim HR, Fridman R, Moon A (2015) Discoidin domain receptor 1 is a novel transcriptional target of ZEB1 in breast epithelial cells undergoing H-Ras-induced epithelial to mesenchymal transition. Int J Cancer 136(6):508–520CrossRefGoogle Scholar
  66. Kolch W, Heidecker G, Lloyd P, Rapp UR (1991) Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature 349(6308):426–428PubMedCrossRefGoogle Scholar
  67. Kondoh H, Kamachi Y (2010) SOX-partner code for cell specification: regulatory target selection and underlying molecular mechanisms. Int J Biochem Cell Biol 42:391–399PubMedCrossRefGoogle Scholar
  68. Krebs AM, Mitschke J, LasierraLosada M, Schmalhofer O, Boerries M, Busch H, Boettcher M, Mougiakakos D, Reichardt W, Bronsert P, Brunton VG, Pilarsky C, Winkler TH, Brabletz S, Stemmler MP, Brabletz T (2017) The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell Biol 19(5):518–529PubMedCrossRefGoogle Scholar
  69. Lake D, Correa SA, Muller J (2016) Negative feedback regulation of the ERK1/2 MAPK pathway. Cell Mol Life Sci 73:4397–4413PubMedPubMedCentralCrossRefGoogle Scholar
  70. Lambert JM, Lambert QT, Reuther GW, Malliri A, Siderovski DP, Sondek J, Collard JG, Der CJ (2002) Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism. Nat Cell Biol 4(8):621–625PubMedCrossRefGoogle Scholar
  71. Lange-Carter CA, Johnson GL (1994) Ras-dependent growth factor regulation of MEK kinase in PC12 cells. Science 265(5177):1458–1461PubMedCrossRefGoogle Scholar
  72. Lee JM, Dedhar S, Kalluri R, Thompson EW (2006) The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172(7):973–981PubMedPubMedCentralCrossRefGoogle Scholar
  73. Lim KH, Counter CM (2005) Reduction in the requirement of oncogenic RAS signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell 8(5):381–392PubMedCrossRefGoogle Scholar
  74. Lim KH, O'Hayer K, Adam SJ, Kendall SD, Campbell PM, Der CJ, Counter CM (2006) Divergent roles for RALA and RALB in malignant growth of human pancreatic carcinoma cells. Curr Biol 16:2385–2394PubMedCrossRefGoogle Scholar
  75. Lin SR, Tsai JH, Yang YC, Lee SC (1998) Mutations of K-RAS oncogene in human adrenal tumours in Taiwan. Br J Cancer 77:1060–1065PubMedPubMedCentralCrossRefGoogle Scholar
  76. Lin X, Chen L, Yao Y, Zhao R, Cui X, Chen J, Hou K, Zhang M, Su F, Chen J, Song E (2015) CCL18-mediated down-regulation of miR98 and miR27b promotes breast cancer metastasis. Oncotarget 6(24):20485–20499PubMedPubMedCentralGoogle Scholar
  77. Liu Y, Sánchez-Tilló E, Lu X, Huang L, Clem B, Telang S, Jenson AB, Cuatrecasas M, Chesney J, Postigo A, Dean DC (2014) The ZEB1 transcription factor acts in a negative feedback loop with miR200 downstream of Ras and Rb1 to regulate Bmi1 expression. J Biol Chem 289(7):4116–4125PubMedCrossRefGoogle Scholar
  78. Liu Y, Zhang M, Qian J, Bao M, Meng X, Zhang S, Zhang L, Zhao R, Li S, Cao Q, Li P, Ju X, Lu Q, Li J, Shao P, Qin C, Yin C (2015) miR-134 functions as a tumor suppressor in cell proliferation and epithelial-to-mesenchymal transition by targeting K-RAS in renal cell carcinoma cells. DNA Cell Biol 34(6):429–436PubMedPubMedCentralCrossRefGoogle Scholar
  79. Lu X, Guo H, Chen X, Xiao J, Zou Y, Wang W, Chen Q (2016) Effect of RhoC on the epithelial-mesenchymal transition process induced by TGF-β1 in lung adenocarcinoma cells. Oncol Rep 36(6):3105–3112PubMedPubMedCentralCrossRefGoogle Scholar
  80. Lusk JB, Lam VY, Tolwinski NS (2017) Epidermal growth factor pathway signaling in drosophila embryogenesis: tools for understanding cancer. Cancers (Basel) 9(2):Pii: E16CrossRefGoogle Scholar
  81. Ma L, Teruya-Feldstein J, Weinberg RA (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449:682–688PubMedCrossRefGoogle Scholar
  82. Marchetti A, Colletti M, Cozzolino AM, Steindler C, Lunadei M, Mancone C, Tripodi M (2008) RK5/MAPK is activated by TGFβ in hepatocytes and required for the GSK-3β-mediated snail protein stabilization. Cell Signal 20(11):2113–2118PubMedCrossRefGoogle Scholar
  83. Maruta H, Burgess AW (1996) Regulation of the Ras signaling network. BioEssays 16(7):139–180Google Scholar
  84. McKay MM, Morrison DK (2007) Integrating signals from RTKs to ERK/MAPK. Oncogene 26(22):3113–3121PubMedCrossRefGoogle Scholar
  85. McKenna WG, Weiss MC, Endlich B, Ling CC, Bakanauskas VJ, Kelsten ML, Muschel RJ (1990) Synergistic effect of the v-myc oncogene with H-RAS on radioresistance. Cancer Res 50(1):97–102PubMedGoogle Scholar
  86. Medarde AF, Santos E (2011) Ras in cancer and developmental diseases. Genes and. Cancer 2(3):344–335Google Scholar
  87. Miller AC, Kariko K, Myers CE, Clark EP, Samid D (1993) Increased radioresistance of EJ Ras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21 Ras isoprenylation. Int J Cancer 53(3):302–307PubMedCrossRefGoogle Scholar
  88. Miyakura Y, Sugano K, Fukayama N, Konishi F, Nagai H (2002) Concurrent mutations of K-RAS oncogene at codons 12 and 22 in colon cancer. Jpn J Clin Oncol 32:219–221PubMedCrossRefGoogle Scholar
  89. Miyazono K (2009) Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proc Jpn Acad Ser B Phys Biol Sci 85(8):314–323PubMedPubMedCentralCrossRefGoogle Scholar
  90. Morrison DK, Cutler RE (1997) The complexity of Raf-1 regulation. Curr Opin Cell Biol 9(2):174–179PubMedCrossRefGoogle Scholar
  91. Murillo MM, Zelenay S, Nye E, Castellano E, Lassailly F, Stamp G, Downward J (2014) RAS interaction with PI3K p110a is required for tumorinducedangiogenesis. J Clin Invest 124:3601–3611PubMedPubMedCentralCrossRefGoogle Scholar
  92. Naguib A, Wilson CH, Adams DJ, Arends MJ (2011) Activation of K-RAS by co-mutation of codons 19 and 20 is transforming. J Mol Signal 6:2PubMedPubMedCentralCrossRefGoogle Scholar
  93. Oktay M, Wary KK, Dans M, Birge RB, Giancotti FG (1999) Integrin-mediated activation of focal adhesion kinase is required for signaling to Jun NH2-terminal kinase and progression through the G1 phase of the cell cycle. J Cell Biol 145(7):1461–1469PubMedPubMedCentralCrossRefGoogle Scholar
  94. Ouerhani S, Bougatef K, Soltani I, Elgaaied IBA, Abbes S, Menif S (2013) The prevalence and prognostic significance of K-RAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer. Mol Biol Rep 40:4109–4114PubMedCrossRefGoogle Scholar
  95. Peschard P, McCarthy A, Leblanc-Dominguez V, Yeo M, Guichard S, Stamp G, Marshall CJ (2012) Genetic deletion of RALA and RALB small GTPases reveals redundant functions in development and tumorigenesis. Curr Biol 22:2063–2068PubMedCrossRefGoogle Scholar
  96. Prior I, Lewis P, Mattos C (2012) A comprehensive survey of Ras mutations in cancer. Cancer Res 72(10):2457–2467PubMedPubMedCentralCrossRefGoogle Scholar
  97. Qi L, Sun B, Liu Z, Cheng R, Li Y, Zhao X (2014) Wnt3a expression is associated with epithelial-mesenchymal transition and promotes colon cancer progression. J Exp Clin Cancer Res 33(1):10CrossRefGoogle Scholar
  98. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A (1992) The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 70(3):401–410PubMedCrossRefGoogle Scholar
  99. Rinehart-Kim J, Johnston M, Birrer M, Bos T (2000) Alterations in the gene expression profile of MCF-7 breast tumor cells in response to c-Jun. Int J Cancer 88:180–190PubMedCrossRefGoogle Scholar
  100. Roux PP, Blenis J (2004) ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68:320–344PubMedPubMedCentralCrossRefGoogle Scholar
  101. Rozengurt E (2007) Mitogenic signaling pathways induced by G protein-coupled receptors. J Cell Physiol 213(3):589–602PubMedCrossRefGoogle Scholar
  102. Saitoh M, Endo K, Furuya S, Minami M, Fukasawa A, Imamura T, Miyazawa K (2016) STAT3 integrates cooperative Ras and TGF-β signals that induce snail expression. Oncogene 35(8):1049–1057PubMedCrossRefGoogle Scholar
  103. Santamaria PG, Moreno-Bueno G, Portillo F, Cano A (2017) EMT: present and future in clinical oncology. Mol Oncol 11(7):718–738PubMedPubMedCentralCrossRefGoogle Scholar
  104. Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, de Schutter J, de Roock W, Salzman DW, Zhang W, Yang D, Pilati C, Bouché O, Piessevaux H, Tejpar S (2014) A let-7 microRNA-binding site polymorphism in K-RAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. Clin Cancer Res 20:4499–4510PubMedPubMedCentralCrossRefGoogle Scholar
  105. Schaap D, van der Wal J, Howe LR, Marshall CJ, van Blitterswijk WJ (1993) A dominant-negative mutant of raf blocks mitogen-activated protein kinase activation by growth factors and oncogenic p21Ras. J Biol Chem 268(27):20232–20236PubMedGoogle Scholar
  106. Shields MA, Ebine K, Sahai V, Kumar K, Siddiqui K, Hwang RF, Grippo PJ, Munshi HG (2013). Snail cooperates with KrasG12D to promote pancreatic fibrosis. Mol Cancer Res 2013 11(9):1078–1087Google Scholar
  107. Simanshu DK, Nissley DV, McCormick F (2017) RAS proteins and their regulators in human disease. Cell 170(1):17–33PubMedPubMedCentralCrossRefGoogle Scholar
  108. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, Settleman J (2009) A gene expression signature associated with “K-RAS addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell 15(6):489–500PubMedPubMedCentralCrossRefGoogle Scholar
  109. Sklar MD (1988) The Ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science 239(4840):645–647PubMedCrossRefGoogle Scholar
  110. Smith G, Bounds R, Wolf H, Steele RJC, Carey FA, Wolf CR (2010) Activating K-RAS mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicine. Br J Cancer 102:693–703PubMedPubMedCentralCrossRefGoogle Scholar
  111. Song C, Satoh T, Edamatsu H, Wu D, Tadano M, Gao X, Kataoka T (2002) Differential roles of Ras and Rap1 in growth factor-dependent activation of phospholipase C epsilon. Oncogene 21(53):8105–8113PubMedCrossRefGoogle Scholar
  112. Stephen AG, Esposito D, Bagni RK, McCormick F (2002) Dragging RAS back in the ring. Cancer Cell 25:272–281CrossRefGoogle Scholar
  113. Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, O'Brien C, Spoerke J, Jhunjhunwala S, Boyd Z, Januario T, Newman RJ, Yue P, Bourgon R, Modrusan Z, Stern HM, Warming S, de Sauvage FJ, Amler L, Yeh RF, Dornan D (2011) miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer. Sci Signal l4(186):pt5Google Scholar
  114. Tall GG, Barbieri MA, Stahl PD, Horazdovsky BF (2001) Ras-activated endocytosis is mediated by the Rab5 guanine nucleotide exchange activity of RIN1. Dev Cell 1(1):73–82PubMedCrossRefGoogle Scholar
  115. Tape CJ, Ling S, Dimitriadi M, McMahon KM, Worboys JD, Leong HS, Norrie IC, Miller CJ, Poulogiannis G, Lauffenburger DA, Jørgensen C (2016) Oncogenic KRAS regulates tumor cell signaling via stromal reciprocation. Cell 165(4):910–920PubMedPubMedCentralCrossRefGoogle Scholar
  116. Tothova Z, Ebert BL (2017) Doubling down on mutant RAS can MEK or break leukemia. Cell 168(5):749–750PubMedCrossRefGoogle Scholar
  117. Trahey M, McCormick F (1987) A cytoplasmic protein stimulates normal N-RASp21 GTPase, but does not affect oncogenic mutants. Science 238(4826):542–545PubMedCrossRefGoogle Scholar
  118. Tulchinsky E, Pringle JH, Caramel J, Ansieau S (2014) Plasticity of melanoma and EMT-TF reprogramming. Oncotarget 5(1):1–2PubMedCrossRefGoogle Scholar
  119. Varras MN, Koffa M, Koumantakis E, Ergazaki M, Protopapa E, Michalas S, Spandidos DA (1996) Ras gene mutations in human endometrial carcinoma. Oncology 53(6):505–510PubMedCrossRefGoogle Scholar
  120. Verde P, Casalino L, Talotta F, Yaniv M, Weitzman JB (2007) Deciphering AP-1 function in tumorigenesis: fra-ternizing on target promoters. Cell Cycle 6(21):2633–2639PubMedCrossRefGoogle Scholar
  121. Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ, Clark GJ (2003a) RASSF2 is a novel K-RAS-specific effector and potential tumor suppressor. J Biol Chem 278(30):28045–28051PubMedCrossRefGoogle Scholar
  122. Vos MD, Martinez A, Ellis CA, Vallecorsa T, Clark GJ (2003b) The proapoptotic Ras effector Nore1 may serve as a Ras-regulated tumor suppressor in the lung. J Biol Chem 278(24):21938–21943PubMedCrossRefGoogle Scholar
  123. Wanami LS, Chen HY, Peiró S, García de Herreros A, Bachelder RE (2008) Vascular endothelial growth factor-a stimulates snail expression in breast tumor cells: implications for tumor progression. Exp Cell Res 314(13):2448–2453PubMedPubMedCentralCrossRefGoogle Scholar
  124. Welsch ME, Kaplan A, Chambers JM, Stokes ME, Bos PH, Zask A, Zhang Y, Sanchez-Martin M, Badgley MA, Huang CS, Tran TH, Akkiraju H, Brown LM, Nandakumar R, Cremers S, Yang WS, Tong L, Olive KP, Ferrando A, Stockwell BR (2017) Multivalent small-molecule pan-RAS inhibitors. Cell 168(5):878–889.e29PubMedPubMedCentralCrossRefGoogle Scholar
  125. Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, Bishop WR, Pai JK (1997) K- and N-RAS are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272:14459–14464PubMedCrossRefGoogle Scholar
  126. Yamauchi J, Miyamoto Y, Tanoue A, Shooter EM, Chan JR (2005) Ras activation of a Rac1 exchange factor, Tiam1, mediates neurotrophin-3- induced Schwann cell migration. Proc Natl Acad Sci U S A 102(41):14889–14894PubMedPubMedCentralCrossRefGoogle Scholar
  127. Yan M, Dai T, Deak JC, Kyriakis JM, Zon LI, Woodgett JR, Templeton DJ (1994) Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1. Nature 372(6508):798–800PubMedCrossRefGoogle Scholar
  128. Yang L, Lin C, Liu ZR (2006) p68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing Axin from beta-catenin. Cell 127(1):139–155PubMedCrossRefGoogle Scholar
  129. Yang F, Sun L, Li Q, Han X, Lei L, Zhang H, Shang Y (2012) SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities. EMBO J 31:110–123PubMedCrossRefGoogle Scholar
  130. Ye K, Wang S, Zhang H, Han H, Ma B, Nan W (2017) Long noncoding RNA GAS5 suppresses cell growth and epithelial-mesenchymal transition in osteosarcoma by regulating the miR-221/ARHI pathway. J Cell Biochem.
  131. Zhadanov AB, Provance DW Jr, Speer CA, Coffin JD, Goss D, Blixt JA, Reichert CM, Mercer JA (1999) Absence of the tight junctional protein AF-6 disrupts epithelial cell–cell junctions and cell polarity during mouse development. Curr Biol l9(16):880–888CrossRefGoogle Scholar
  132. Zhang C, Spevak W, Zhang Y, Burton EA, Ma Y, Habets G, Zhang J, Lin J, Ewing T, Matusow B, Tsang G, Marimuthu A, Cho H, Wu G, Wang W, Fong D, Nguyen H, Shi S, Womack P, Nespi M, Shellooe R, Carias H, Powell B, Light E, Sanftner L, Walters J, Tsai J, West BL, Visor G, Rezaei H, Lin PS, Nolop K, Ibrahim PN, Hirth P, Bollag G (2015) RAF inhibitors that evade paradoxical MAPK pathway activation. Nature 526:583–586PubMedCrossRefGoogle Scholar
  133. Zhang K, Myllymäki SM, Gao P, Devarajan R, Kytölä V, Nykter M, Wei GH, Manninen A (2017) Oncogenic K-Ras upregulates ITGA6 expression via FOSL1 to induce anoikis resistance and synergizes with αV-class integrins to promote EMT. Oncogene 36(41):5681–5694PubMedPubMedCentralCrossRefGoogle Scholar
  134. Zhou Y, Prakash P, Liang H, Cho KJ, Gorfe AA, Hancock JF (2017) Lipid-sorting specificity encoded in K-Ras membrane anchor regulates signal output. Cell 168:239–251PubMedCrossRefGoogle Scholar
  135. Zhu S, Zhang J, Xu F, Xu E, Ruan W, Ma Y, Huang Q, Lai M (2015) IGFBP-rP1 suppresses epithelial-mesenchymal transition and metastasis in colorectal cancer. Cell Death Dis 6:e1695PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© The International CCN Society 2018

Authors and Affiliations

  1. 1.Department of BiochemistryUniversity of LucknowLucknowIndia

Personalised recommendations